Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are metabolic liver disorders of increasing importance. There are frequently associated with obesity, diabetes mellitus, hyperlipidemia and insulin resistance. NAFLD can progress to NASH, and NASH to cirhosis, liver failure, and hepatocellular carcinoma. Many drugs have been tried in treatment of NASH. The insulin sensitizing medicines as metformin, thiazolidinediones, antioxidant treatment, have shown promising results. Unfortunately, there is lack of controlled trials of growing numbers of anti-NASH drugs.